Joseph Michael Moates, M.D.

OFFICE :                University of Alabama at Birmingham

                                 Department of Medicine

                                 Division of Endocrinology & Metabolism

E:mail joseph.moates@va.gov

EDUCATION: B.S.Biomedical Engineering, 1984

Vanderbilt University, Nashville, TN.

Pre-Medicine/Non-Degree 1985-86, University of Alabama

at Birmingham, Birmingham, AL.

M.D. 1990 University of Alabama at

Birmingham, Birmingham, AL.

ACADEMIC AND PROFESSIONAL APPOINTMENTS:

(Current) Assistant Professor of Medicine, University of Alabama at Birmingham, School of Medicine, Birmingham, AL, Staff Physician, VA Medical Center, Birmingham, AL

Assistant Professor of Medicine & Cell Biology, Baylor College of Medicine, Houston, TX. Staff Physician, VA Medical Center, Houston, TX.

Instructor in Medicine and Research Associate, Vanderbilt University Medical Center, VA Medical Center, Nashville, TN.

Clinical Endocrinology Fellow and Research Associate, Vanderbilt University Medical Center, Nashville, TN.

Resident, Internal Medicine and Research Associate, Clinical Investigator Pathway, Vanderbilt University Medical Center, Nashville, TN.

Howard Hughes Research Scholars Program, The National Institutes of Health, Bethesda, MD.

Honors and Awards:

Siegler Foundation Grant, Winter 2002

VA Merit Review Grant Recipient, Spring 2001-2004

Baylor College of Medicine Seed Funds, 1999-2000

Career Development Award, Veterans Administration 1997-2001

Recipient of Grant Liddle Scholarship Award, Vanderbilt University 1995-96

Juvenile Diabetes Foundation Post-Doctoral Fellowship, 1995-1997.

Howard Hughes Research Scholars Program, National Institutes of Health, 1987-88.

Diabetes Summer Research Program, Vanderbilt University, Nashville, TN, 6/86-8/86.

Maud Glover Folsom Foundation, Fellow and Scholarship recipient, 1980-90.

Board Certifications:

Diplomate, American Board of Internal Medicine, 1993, 2004

Board Eligible, Endocrinology 6/97

MEDICAL LICENSES:

State of TN

State of AL

Workshops:

JDF sponsored Diabetes research workshop June 1995, Copenhagen, Denmark

Former Grant Support:

VA MERIT Review, awarded and active

Spring 2001-Spring 2004

“Regulation of glucokinase gene expression”

Career Development Award, Veterans Administration 1997-2001

“Regulation of glucokinase gene expression”

Trainees Mentored:

Eva Caudell, Ph.D., Research Associate, 7/’01 to 7/’02

Ambika Ashraf, M.D., Pediatric Endocrinology Fellow, Research Associate, 4/’04 to 12/’04

University Committees:

UAB IACUC, Fall 2002 to Spring 2005

PEER REVIEWED PUBLICATIONS:

1. Isolation and Characterization of the Human Thyrotropin b-Subunit Gene: Differences in Gene Structure and Promoter Function from Murine Species. Wondisford, F.E., Radovick, S., Moates, J.M., Usala, S.J., and Weintraub, B.D.: J. Biol. Chem. 1988, Sept. 5; 263(25):12538-42.

2. Thyroid Hormone Inhibition of Human Thyrotropin b-Subunit; Gene Expression is Mediated by a cis-Acting Element in the First Exon. Wondisford, F.E., Farr, E.A., Radovick, S., Moates, J.M., Steinfelder, H.J., and Weintraub, B.D.: J. Biol. Chem. 1989, Sept. 5; 264(25):14601-4.

3. Glucokinase in extrapancreatic neural and neuroendocrine cells. T.L. Jetton, C. Postic, K.D. Niswender, J.M. Moates, M.A. Magnuson. In Diabetes, S. Baba & T. Kaneko eds., 1994.

4. Characterization of the Pal Motifs in the Upstream Glucokinase Promoter: Binding of a Cell Type-Specific Protein Complex Correlates with Transcriptional Activation. J. Micheal Moates, Kathy D. Shelton, and Mark A. Magnuson, Mol. Endo. 1996,10: 723-731.

5. Variable Expresion of Hepatic Glucokinase in Mice is Due to a Regulational Locus That Cosegregates with the Glucokinase Gene. J.M. Moates, C. Postic, J.F. Decaux, J. Girard, and M.A. Magnuson, Genomics. 1997, 45: 185-193.

6. Targeted oncogenesis of hormone-negative pancreatic islet progenitor cells. Thomas L. Jetton, J. Michael Moates, Jill Lindner, C.V.E. Wright, and Mark A. Magnuson, Proc. Natl. Acad. Sci., 1998, 95, 8654-8659. Co-first author.

7. Activation of Glycine and Glutamate Receptors Increases Intracellular Calcium in Cells Derived From the Endocrine Pancreas. C.D. Weaver, J.G. Partridge, T.L. Yao, J.M. Moates, M.A. Magnuson, and T.A. Verdoorn, , Molecular Pharmacology, 1998, 54(4), 639-646.

8. Dual role for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using cre recombinase. Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A., J. Biol. Chem., 1999, 274(1), 305-315,

9. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Davis EA, Cuesta-Munoz A, Raoul M, Buettger C, Sweet I, Moates M, Magnuson MA, Matschinsky FM., Diabetologia 1999 Oct;42(10):1175-86

10. The Glucokinase System and the Regulation of Blood Sugar. Matschinsky, F.M., Davis, E., Cuesta-Munoz, A. Buettger, C., Sweet, J., Moates, M., Magnuson, M.A. In Molecular Pathogenesis of MODYs. Eds. F.M. Matschinsky and M.A. Magnuson. S. Karger. Basel, Switzerland, 2000.

11. BETA2 Activates Transcription from the Upstream Glucokinase Gene Promoter in Islet b- and Gut-endocrine Cells. Mike Moates, Sarmistha Nanda, Michelle Cissell, Ming-Jer Tsai, and Roland Stein, Diabetes, 2003, Feb;52, 403-408.

12. The Pal elements in the upstream glucokinase promoter exhibit dyad symmetry and display cell-specific enhancer activity when multimerized.  J.M. Moates and Mark A. Magnuson, Diabetologia, September, 2004, 1632-1640.

13. An Unusual Case of Neonatal Diabetes Mellitus Due to Pancreas Agenesis. Ambika Ashraf, Hussein Abdullatif, William Hardin, & J.M. Moates. In Press, Pediatric Diabetes.

INVITED (non-Peer reviewed) ARTICLES

1. “Islet Cell Transplant” Michael Moates, Alabama Diabetes Monitor, Vol. 1, Issue 4, Summer 2003.

ABSTRACTS:

1. The Palindromic Repeat Elements in the Upstream Glucokinase Promoter are Determinants of Neuroendocrine Cell-Specific Transcription. J.M. Moates, K.D. Shelton, M.A. Magnuson. Abstract presented at The 1993 Endocrine Society Meeting.

2. Targeted Oncogenesis of Specific Neuro- endocrine Cells in Transgenic Mice Using Upstream Glucokinase Promoter Sequences. Thomas L. Jetton, J. Michael Moates , Jill Lindner, Yin Liang, Andras Khoor, Franz M. Matschinsky, Mark A. Magnuson, Nashville, TN. 1995 ADA Meeting.

3. Immortalization and Comparison of Neuroendocrine Cells that Express Glucokinase. J. Michael Moates, Thomas L. Jetton, Mark A. Magnuson, Nashville, TN. 1995 ADA Meeting.

4. Detection and Characterization of Functional Ionotropic Glutamate Receptors in the Murine Insulinoma Cell Line GK-P3. David C. Weaver, J. Michael Moates, Mark A. Magnuson, Todd A. Verdoorn, Nashville, TN. 1995 ADA Abstracts.

5. Contact Points for the Pal-binding Proteins Define Elements in the Upstream Glucokinase Promoter Essential For Transcription. J.M. Moates and M.A. Magnuson, Nashville, TN, 1997 Keystone Symposium, Park City, UT.

6. Different Hepatic Glucokinase Activity Alleles in Mice Cosegregate with the Glucokinase Gene. J.M. Moates, C. Postic, J.F. Decaux, J. Girard, E. Leiter and M.A. Magnuson, 1997 Endocrine Society Meeting.

7. Transformation of a putative pancreatic b cell precursor: Defining transcriptional determinants and functional markers for b cell maturation. Thomas L. Jetton, J. Michael Moates, Jill Lindner, and Mark A. Magnuson. Nashville, TN. 1998 ADA Meeting.

8. Liver and Pancreatic b cell-specific Gene Knock-outs of Glucokinase (GK) using Cre-loxP Reveal Cell-Specific Roles for the Enzyme in Glucose Homeostasis. Catherine Postic, Thomas L. Jetton, Masakazu Shiota, Kevin D. Niswender, Yuejin Chen, Mike Moates, Kathy D. Shelton, Jill Lindner & Mark A. Magnuson, Nashville, TN. 1998 ADA Meeting.

9. Contact Point Analysis, Point Mutagenesis, and Transfection Analysis of the Pal Elements in the Upstream Glucokinase (bGK) Promoter Define These Elements as Novel Neuroendocrine Cell Type-specific Enhancers. Mike Moates and Mark A. Magnuson. Nashville, TN, 1998 ADA Meeting.

10. A Minimal Model of Glucose Induced Insulin Release Accurately Predicts Alterations of Glucose Homeostasis Caused by Glucokinase Mutations in MODY-2 and GK-Linked Hypoglycemia. Franz Matschinsky, Elizabeth Davis, Antonio Cuesta-Munoz, Ian Sweet, Carol Buettger, Michael Moates, and Mark Magnuson, 1998 ADA Meeting.

11. Binding of the bHLH transcription factor BETA2 to an E-box regulatory motif in the glucokinase gene promoter. Mike Moates and Lisa Kelly, Keystone Meeting on Diabetes, Taos NM, 2000.

12. The Transcription Factor BETA2 Binds to and Trans-Activates an E-Box Regulatory Motif in the Glucokinase Gene Promoter. Mike Moates and Lisa Kelly, ADA Mtg., San Antonio, TX, 6/2000.

13. Glucokinase Gene Transcription in Neuroendocrine Cells Requires Pal Element Binding Protein Dimerization. Y. Asai, J.M. Moates, C.J. Barrick, and M.A. Magnuson. Poster, 2002 ADA Mtg. San Francisco.

14. Ductal gut cell types generated in embryonic stem cell-derived teratomas. Georgia Ali, Mike Moates, Keystone Symposium, 2004.

15. High similarity of gut- and islet-derived neuroendocrine cells revealed by transcriptome analysis. Mike Moates, 2004 Endocrine Society Meeting, New Orleans, LA

16. An Unusual Case of Neonatal Diabetes Mellitus Due to Pancreas Agenesis. Ambika Ashraf, J.M. Moates. SSCI, Accepted for Oral presentation, Feb. 2005.

INVITED TALKS:

Contact points for the Pal-binding proteins define elements in the upstream glucokinase promoter essential for transcription. J.M. Moates and M.A. Magnuson, Nashville, TN,1997 Keystone Symposium, Park City, UT.

Endocrine Grand Rounds, 10/98, Baylor College of Medicine, Houston, TX

Endocrine Grand Rounds, 10/98, Univ. of Nebraska, Omaha, NE

Endocrine Grand Rounds, 11/98, Univ. of Iowa, Iowa City, IA

Endocrine Grand Rounds, Jan. 2002, UAB

Endocrine Grand Rounds, October 2002, UAB

Endocrine Grand Rounds, September 2003, UAB

Teaching Experience 1998-2004

1. VA Inservice 9/98 Clinical Issues in the Management of Diabetes (To Medical Interns)-

2 times

2. BCM Research Conference/Dinner 1998-”Regulation and Expression of the Glucokinase Gene”

3. VA Inservice 12/98 Clinical Issues in the Management of Diabetes

To Rehab department

4. Clinical Pathophysiology Course

10/98 4-1 hr group sessions

5. BCM Grand Rounds “Clinical Management Issues in Hypoparathyroidism”

April 1, 1999

6. Endocrine fellows Friday Research Conference (1 hr lecture) entitled

“Examining Diabetes Genes” 6/25/99

7. Residents Noon Conference (1 hr lecture) entitled

“Diabetic Ketoacidosis” 7/28/99

8. Fellows Noon Conference (1 hr lecture) entitled

” Diabetic Ketoacidosis” 9/24/99

10. VA Medical Grand Rnds. entitled

“Recent Advances in the Management of Type 2 Diabetes” 10/18/99

11. Residents Noon Conference (1 hr lecture) entitled

“Diabetic Ketoacidosis” 10/20/99

12. Residents Noon Conference (1 hr lecture) entitled

“Diabetic Ketoacidosis” 10/26/99

13. Clinical Pathophysiology Course

10/99 4 hrs, group leader

14. Fellows Noon Conference (1 hr lecture) entitled

“Regulation of Gene Expression” 10/29/99

15. VA Inservice 4/12/00, Update in the Management of Type II Diabetes

to Medical Interns

16. VA Inservice 4/12/00 Update in the Management of Type II Diabetes

to Medical Interns

18. VA Inservice (30 min lecture) 7/25/00 Update in the Management of Type I

Diabetes To Medical Interns

19. Inservice (30 min lecture) 7/27/00 Update in the Management of Type II

Diabetes to Medical Interns

20. Residents Noon Conference (1 hr lecture) entitled

“Diabetic Ketoacidosis” 7/26/00

21. VA Medical Grand Rnds. (30 min seminar) entitled

“Insulin Therapy for Type 2 Diabetes” 8/28/00

22. BCM Endocrine Research Dinner 2001 (30 min seminar)

“Regulation of Glucokinase Gene Expression” 12/00

23. VA Medical Grand Rnds. (50 min seminar) entitled

“The ABC’s of TZDs” 05/21/01

24. Endocrine Fellows Research Conference

October 12, 2001 “Regulation of Gene Expression”

25. Clinical Pathophysiology Course

10/01 4-1 hr group sessions

26. Endocrine Fellows Research Conference

Dec. 14, 2001 “Mechanisms of TZD function and fat biology”

27. Endocrine Grand Rounds, Jan. 2002

“Put the sugar in the fat: Why patients on TZDs gain weight”

28. Endocrinology Research Conference May 14, 2002

“Engineering apoptosis in adipocytes”

29. Lufkin, TX VA Outpatient Grand Rounds June 12, 2002

1 hr lecture “Recent Advances in the Management of Type 2 Diabetes”

30. Beaumont, TX VA Outpatient Grand Rounds June 12, 2002

1 hr lecture “Recent Advances in the Management of Type 2 Diabetes”

31. UAB Endocrine Grand Rounds, October 3, 2002

1 hr lecture “Resetting the ‘adipostat’ using PPAR? agonists”

32. UAB Clinical Pathophysiology Course Small group leader

Spring 2003, 2 hrs teaching credit

33. Endocrine Grand Rounds, September 2003, UAB

“Cell Therapy Prospects for Treating Diabetes”

34. UAB Clinical Pathophysiology Course Small group leader

Spring 2004, 2 hrs teaching credit

35. Department of Geriatrics Grand Rounds, May 2004

“Update in Diabetes Management”

36. Department of Medicine Grand Rounds, August 2004

“Molecular, cellular, and pharmacologic strategies to restore glucose control in Diabetes”

37. Department of Cell Biology Weekly Departmental Seminar, October 2004

“Regulation of Glucokinase Gene Expression”

38. UAB Clinical Pathophysiology Course Small group leader

Spring 2005, 2 hrs teaching credit

39. “Management of Ketoacidosis” Lecture to Medicine Residents Aug. 2005

40. “Management of Ketoacidosis” Lecture to Medicine Residents Aug. 2006

41. “Update in Type 2 Diabetes Management” September 2006, CME course for nurses, Birmingham VA Medical Center, September 2006

42. “Update in Type 2 Diabetes Management” January 2007, CME course for nurses, Birmingham VA Medical Center, January 2007

43. UAB Clinical Pathophysiology Course Small group leader

Spring 2007, 2 hrs teaching credit

44. “Update in Type 2 Diabetes Management” January 2008, CME course for nurses, Birmingham VA Medical Center, January 2008

45. UAB Clinical Pathophysiology Course Small group leader

Spring 2008, 2 hrs teaching credit

Career Synopsis and Biomedical Research Interests:

Dr. Mike Moates received his undergraduate degree in biomedical engineering from Vanderbilt University and his medical degree from the University of Alabama at Birmingham. He did his post-graduate training in internal medicine at Vanderbilt University in Nashville, Tennessee. Followed by a combined research and clinical fellowship at Vanderbilt, Dr. Moates served on the faculty at Baylor College of Medicine in Houston and as a Staff Physician at the Houston VA Medical Center where he was involved in both basic and clinical diabetes research. He is currently an Assistant Professor at UAB School of Medicine in Birmingham, AL and a Staff Physician at the Birmingham VA Medical Center where he is actively involved in the management of patients with diabetes and general endocrine disorders. He is actively involved in the UAB Endocrinology service and teaching of fellows and residents.

.